The fibroblast growth factors (FGFs) comprise a family of at least 18 structurally related polypeptides that play important roles in embryonic development, angiogenesis and wound healing. FGFs exert these diverse effects by binding to and activating a distinct subclass of receptor tyrosine kinases. The mammalian FGF receptor (FGFR) family is composed of four genes (FGFR1-FGFR4). Each FGFR binds a unique repertoire of FGF ligands. The specificity of this binding is determined by differences in primary structure in the extracellular domain as well as alternative splicing. Dimerization is essential for FGFR activation, however, FGFs alone are unable to induce receptor dimerization and activation, requiring heparin-like molecules to facilitate this process. The investigator proposes four specific aims to investigate the molecular mechanisms by which FGFs and heparin sulfate-containing proteoglycans induce receptor dimerization and activation, the structural requirements that impart ligand binding specificity, and the contribution of each subdomain of the extracellular domain to regulation of ligand binding. In addition, the effects of FGFR mutations found in human skeletal disorders on ligand binding will be examined.
These aims will be accomplished by x-ray crystallographic studies combined with biochemical experiments employing cultured cells expressing mutant FGFRs. In addition, the association thermodynamics of FGFs, heparin and the ligand-binding domains of FGFRs will be characterized by isothermal titration calorimetry and BIAcore analysis. These studies will increase our knowledge of FGFR signal transduction and provide a basis for understanding the effects of FGFR mutations that result in human skeletal disorders. Since FGFs are involved in angiogenesis and tumorigenesis, it is anticipated that the results of these structural and functional analyses will facilitate the rational design of novel FGF antagonists for the treatment of cancer as well as enhance our understanding of other heparin-binding growth factors

Agency
National Institute of Health (NIH)
Institute
National Institute of Dental & Craniofacial Research (NIDCR)
Type
Research Project (R01)
Project #
5R01DE013686-05
Application #
6750731
Study Section
Pathobiochemistry Study Section (PBC)
Program Officer
Small, Rochelle K
Project Start
2000-07-01
Project End
2005-06-30
Budget Start
2004-07-01
Budget End
2005-06-30
Support Year
5
Fiscal Year
2004
Total Cost
$368,684
Indirect Cost
Name
New York University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Agoro, Rafiou; Montagna, Anna; Goetz, Regina et al. (2018) Inhibition of fibroblast growth factor 23 (FGF23) signaling rescues renal anemia. FASEB J 32:3752-3764
Liang, Guang; Song, Lintao; Chen, Zilu et al. (2018) Fibroblast growth factor 1 ameliorates diabetic nephropathy by an anti-inflammatory mechanism. Kidney Int 93:95-109
Chen, Gaozhi; Liu, Yang; Goetz, Regina et al. (2018) ?-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling. Nature 553:461-466
Xu, C; Lang-Muritano, M; Phan-Hug, F et al. (2017) Genetic testing facilitates prepubertal diagnosis of congenital hypogonadotropic hypogonadism. Clin Genet 92:213-216
Somm, Emmanuel; Henry, Hugues; Bruce, Stephen J et al. (2017) ?-Klotho deficiency protects against obesity through a crosstalk between liver, microbiota, and brown adipose tissue. JCI Insight 2:
Huang, Zhifeng; Tan, Yi; Gu, Junlian et al. (2017) Uncoupling the Mitogenic and Metabolic Functions of FGF1 by Tuning FGF1-FGF Receptor Dimer Stability. Cell Rep 20:1717-1728
Johnson, Kristen; Levine, Kymberly; Sergi, Joseph et al. (2017) Therapeutic Effects of FGF23 c-tail Fc in a Murine Preclinical Model of X-Linked Hypophosphatemia Via the Selective Modulation of Phosphate Reabsorption. J Bone Miner Res 32:2062-2073
Xu, Cheng; Messina, Andrea; Somm, Emmanuel et al. (2017) KLB, encoding ?-Klotho, is mutated in patients with congenital hypogonadotropic hypogonadism. EMBO Mol Med 9:1379-1397
Chen, Huaibin; Marsiglia, William M; Cho, Min-Kyu et al. (2017) Elucidation of a four-site allosteric network in fibroblast growth factor receptor tyrosine kinases. Elife 6:
Liu, Yang; Ma, Jinghong; Beenken, Andrew et al. (2017) Regulation of Receptor Binding Specificity of FGF9 by an Autoinhibitory Homodimerization. Structure 25:1325-1336.e3

Showing the most recent 10 out of 91 publications